Literature DB >> 21917318

Genetic polymorphisms in the serotonergic system and symptom clusters of major depressive disorder.

Mitsuhiro Kamata1, Akihito Suzuki, Keizo Yoshida, Hitoshi Takahashi, Hisashi Higuchi, Koichi Otani.   

Abstract

BACKGROUND: It has been suggested that the symptoms of major depressive disorder (MDD) are composed of some clusters, which are linked to distinct genetic mechanisms. The purpose of this study was to examine the associations of genetic polymorphisms in the serotonergic system with three factors of the Montgomery-Åsberg Depression Rating Scale (MADRS), i.e., dysphoria, retardation, and vegetative symptoms.
METHODS: The subjects were 132 Japanese patients of MDD. The genotypes of tryptophan hydroxylase 218A/C, serotonin transporter gene-linked polymorphic region (5HTTLPR), and 5HT2A receptor -1438G/A polymorphisms were determined by PCR methods. Statistical analyses were performed by the multiple regression analysis.
RESULTS: The A allele of 5HT2A polymorphism was associated with higher vegetative scores (p=0.001) and total MADRS scores (p=0.005), while the S allele of 5HTTLPR was related to higher dysphoric scores (p=0.012). The tryptophan hydroxylase genotype was not related to any factor scores or total MADRS scores. LIMITATIONS: The sample size was relatively small, and the subjects were composed of Japanese only.
CONCLUSION: This study suggests that the genetic polymorphisms in 5HT2A receptor and serotonin transporter are linked to discrete symptom clusters of MDD.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917318     DOI: 10.1016/j.jad.2011.08.027

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

Review 1.  Genetic endophenotypes for insomnia of major depressive disorder and treatment-induced insomnia.

Authors:  Ibrahim Mohammed Badamasi; Munn Sann Lye; Normala Ibrahim; Johnson Stanslas
Journal:  J Neural Transm (Vienna)       Date:  2019-05-18       Impact factor: 3.575

2.  Brain moderators supporting the relationship between depressive mood and pain.

Authors:  Adrienne L Adler-Neal; Nichole M Emerson; Suzan R Farris; Youngkyoo Jung; Robert C Coghill; Fadel Zeidan
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

3.  A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression.

Authors:  Vesa Paavonen; Olli Kampman; Ari Illi; Merja Viikki; Eija Setälä-Soikkeli; Esa Leinonen
Journal:  Psychiatry Investig       Date:  2014-01-21       Impact factor: 2.505

Review 4.  Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

Authors:  Bruno P Guiard; Giuseppe Di Giovanni
Journal:  Front Pharmacol       Date:  2015-03-17       Impact factor: 5.810

5.  Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?

Authors:  Akitsugu Sueki; Eriko Suzuki; Hitoshi Takahashi; Jun Ishigooka
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

6.  Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression.

Authors:  Hitoshi Takahashi; Hisashi Higuchi; Kazuhiro Sato; Mitsuhiro Kamata; Keizo Yoshida; Katsuji Nishimura
Journal:  Neuropsychiatr Dis Treat       Date:  2017-06-07       Impact factor: 2.570

Review 7.  Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder.

Authors:  Xiaojun Shao; Gang Zhu
Journal:  Front Psychiatry       Date:  2020-05-13       Impact factor: 4.157

8.  Serotonin 2A receptor gene (HTR2A) regulatory variants: possible association with severity of depression symptoms in children with autism spectrum disorder.

Authors:  Kenneth D Gadow; Ryan M Smith; Julia K Pinsonneault
Journal:  Cogn Behav Neurol       Date:  2014-06       Impact factor: 1.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.